Screener
Bristol-Myers Squibb BMY EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Earnings/(Loss) before income taxes | 4,086 | 1,773 | 7,326 | 4,744 |
| Income tax provision | 770 | 460 | 1,331 | 969 |
| Net earnings/(loss) | 3,316 | 1,313 | 5,994 | 3,775 |
| Noncontrolling interest | (1) | 2 | — | 9 |
| Net earnings/(loss) attributable to BMS | $3,317 | $1,310 | $5,994 | $3,766 |
| Earnings/(Loss) per common share: | ||||
| Basic | $1.62 | $0.64 | $2.94 | $1.85 |
| Diluted | 1.62 | 0.64 | 2.93 | 1.85 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's EPS (diluted)?
- Bristol-Myers Squibb (BMY) reported EPS (diluted) of $1.62 in Q2 2026.
- How has Bristol-Myers Squibb's EPS (diluted) changed year-over-year?
- Bristol-Myers Squibb's EPS (diluted) increased by 153.1% year-over-year, from $0.64 to $1.62.
- What is the long-term trend for Bristol-Myers Squibb's EPS (diluted)?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's EPS (diluted) has grown at a 2.5% compound annual growth rate (CAGR), from $3.12 to $3.45.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Bristol-Myers Squibb's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude